Creative Bioarray
  • USA:
  • Europe:
LOGO
  • Home
    • About Us
    • Contact Us
    • Events
  • Screening
    • Ionic Screening Service
      • Ion Flux Assay
      • Fluorescence Assay
      • Patch-clamp Assay
    • Ionic Screening Panel
      • Sodium Channels
      • Potassium Channels
      • Chloride Channels
      • Calcium Channels
      • TRP Channels
      • ATP gated P2X Channels
      • ASICs
      • Nicotinic Acetylcholine Receptors
      • Ionotropic Glutamate-gated Receptors
      • GABAa Receptors
      • Glycine Receptors
      • 5-HT Receptors3
      • Cystic Fibrosis Transmembrane Conductance Regulators (CFTR)
      • Other Ion Channels
    • Stable Cell Lines
      • Ion Channel Expressing Cell
      • GPCR Expressing Cell
      • Other Membrane Receptors/Transporters/Exchangers Expression Cell
      • Customized Ionic Channel Expression System
  • Cardiology
    • Cardiac Ion Channel Screen Panels
      • HERG (IKR, KV11.1)
      • Cav1.2
      • Kv4.3
      • KCNQ1/mink/Kv7.1
      • Kir2.1
      • Nav1.5
      • Kv1.5
      • HCN1&HCN4
      • Other Ion Channels
    • CiPA
      • CiPA Cardiac Channel Assays
      • CiPA In silico Modeling
      • CiPA Translational Assays
    • 3D Cardiotoxicity
    • Cardiomyocyte Functions
      • Action Potential Properties
      • Calcium Transient in Cardiomyocytes
      • QT Service Using Langendorff Perfused Heart
    • Cardiac in vivo Assays
      • QRS, QT Waves Detection by ECG
  • Neurology
    • Neurotransmission Functions
      • sEPSC/sIPSC Recordings
      • fEPSP / Populational Spikes Recordings
      • LTP & LTD Formation or Deficit Detection
    • Basic Neuronal Activity
      • Action Potential Properties Assay
      • NMDA/AMPA Ratio Test
      • Calcium Signaling Test
      • Customized Electrophysiological Test
    • Neuronal in vivo Assays
      • In vivo Extra-cellular Recordings/Whole-cell Patch-clamp Recordings
      • Continuous Telemetric EEG Recordings
    • Animal Behavior Tests
      • Spontaneous Locomotor Functions
      • Cognitive Functions
      • Anxiety-Depression and Social Interaction Evaluation
      • Assays for Neuropsychiatric Disorders
  • Ophthalmology
  • Platform
    • Experiment Systems
      • Xenopus Oocyte Screening Model
      • Acute Isolated Cardiomyocytes
      • Acute Dissociated Neurons
      • Primary Cultured Neurons
      • Cultured Neuronal Cell Lines
      • iPSC-derived Cardiomyocytes/Neurons
      • Acute/Cultured Organotypic Brain Slices
      • Oxygen Glucose Deprivation Model
      • 3D Cell Culture
      • iPSC-derived Neurons
      • Isolation and culture of neural stem/progenitor cells
    • Animal Models
      • Alzheimer's Disease Model
      • Parkinson's Disease Model
      • Huntington's Disease Model
      • Epilepsy Model
      • ALS Model
      • Psychiatric Model
      • Autism Spectrum Disorder
      • Cerebral-Spinal Injury Model
      • Pain Model
      • Stroke Model
      • Fragile X Model
      • Acute/Chronic Heart Failure Model
    • Techinques
      • Manual Patch-clamp Technique
      • Automated Patch-clamp
      • Multi-Electrode Array (MEA)
      • FluxOR™ Thallium Assay
      • FLIPR Detection System
      • Optogenetics
      • Neuronal Tract Tracing
    • Resource
      • Technical Methods
      • Neuroscience
      • Channelopathies
      • Channelomics
    • Equipment
  • Order
  • Careers
  • Home
  • Platform
  • Animal Models
  • Huntington's Disease Model
  • Screening
  • Ionic Screening Service Ionic Screening Panel Stable Cell Lines
  • Cardiology
  • CiPA 3D Cardiotoxicity Cardiomyocyte Functions Cardiac in vivo Assays Cardiac Ion Channel Screen Panels
  • Neurology
  • Basic Neuronal Activity Neurotransmission Functions Neuronal in vivo Assays Animal Behavior Tests
  • Platform
  • Experiment Systems Animal Models Techinques Resource Equipment

Huntington's Disease Model

Huntington's disease (HD) is an autosomal dominant neurodegenerative genetic disorder affects muscle coordination leading to cognitive decline and psychiatric manifestations. HD patients exhibit a diverse set of symptoms with well-recognized emotional, cognitive and motor components. It typically becomes noticeable at middle age. Although onset is generally within the fourth or fifth decade, the disease can start at any time from early childhood until very old age with a mean duration of 15-20 years. Symptoms of the disease may be different between individuals and among affected members of the same family, but the progress is predictable for most individuals. As the disease advances, patients show uncoordinated, jerky body movements, decline in mental abilities, along with behavioral (physical abilities are gradually impeded until coordinated movement becomes very difficult) and psychiatric problems (mental abilities generally decline into dementia).

HD is mainly caused by the mutation which is an unstable expansion of CAG repeats in the huntingtin gene. The disease is caused by an autosomal dominant mutation of the huntingtin gene (CAG^polyglutamine repeat expansion. Creative Bioarray has phenotypically characterized extensively both transgenic and knock-in models of the disease.


4-2-3 Huntington's Disease Model-1.jpg

Fig.1 A schematic representation of the brain highlighting the striatum and the pathology of HD in a neuronal cell


Two HD animal models are available in Creative Bioarray. The R6/2 transgenic mouse model was the first developed and widely used to understand the pathogenesis of the disease as well as for the evaluation of new therapies. These mice carrying around 120 CAG repeats present severe weight loss, progressive motor, cognitive and psychiatric deficits, and a reduced life expectancy (18-20 weeks). The Q175 Knock-in model derived from a spontaneous expansion from Q140 Knock-in colony, display also a slower progressive motor and cognitive phenotype than the R6/2 model.

Creative Bioarray provides the R6/2 mice model of human Huntington's disease (HD) by expressing a portion of the human HD gene under human gene promoter elements (1 kb of 5 UTR sequence and exon 1 together with ~140 CAG repeats). Expression of this amino-terminal fragment of the huntingtin protein with its polyglutamine expansion is sufficient to reproduce the phenotype of human HD. Both the R6/2 and Q175 mouse models are kept in Creative Bioarray.


4-2-3 Huntington's Disease Model-2.jpg

Fig.2 Effects of 1, 2, and 3% creatine on rotarod performance and on body weight in R6/2 HD transgenic mice


Tests

General test

  • Body weight

Motor functionanalysis

  • Open field test

  • Rotarod test

  • Grip strength test

  • Rear climbing test

Cognitive deficits

  • Two-choice swim test

  • Contextual fear conditioning

Neurological index

  • In vivo brain imaging

  • MRI for brain volumetry (whole brain, cortex, striatum)

  • MRS for striatal metabolites

We also provide immunohistochemistry tests, inflammatory markers staining, iron accumulation and dopaminergic neuro-transmission tests for HD animal model study. To accelerating the identification of treatments for HD, Creative Bioarray has developed customized animal model service in HD research.

References

  1. Ferrante R, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J Neurosci. 2000; 20: 4389–4397.

  2. Zhang N, et al. iPSC-based drug screening for Huntingtons disease. Brain Res. 2016; 1638: 42–56.


For research use only.

Related Section

  • Alzheimer's Disease Model
  • Parkinson's Disease Model
  • Epilepsy Model
  • ALS Model
  • Psychiatric Model
  • Autism Spectrum Disorder
  • Cerebral-Spinal Injury Model
  • Pain Model
  • Stroke Model
  • Fragile X Model
  • Acute/Chronic Heart Failure Model

Inquiry


Subscribe
  • Links
  • Sodium Channels
  • Calcium Channels
  • Potassium Channels
  • Chloride Channels
  • TRP Channels
  • ATP gated P2X Channels
  • ASICs
  • USA
  • Europe

Copyright © 2025 Creative Bioarray. All rights reserved.